FAP Clinical Trial
Cancer Prevention Pharmaceuticals recently closed enrollment for a clinical trial for adults with FAP (familial adenomatous polyposis).
This study combines two oral medications, Sulindac and Eflornithine, to explore and determine:
If combining these two drug treatments can prevent the disease from getting worse, and/or delay major surgery, better than each drug alone,
If the treatment can alter the course of the disease, and
How the medication might impact your quality of life.
What are these drugs? Sulindac is a nonsteroidal anti-inflammatory drug (NSAID), similar to ibuprofen, that is used to treat pain, fever, and inflammation. Sulindac has also been by doctors to manage polyp growth in FAP patients, although this use is not yet approved by the FDA.
Eflornithine (CPP-1x) is a new drug, not yet for sale.
In combination, the drugs have been shown to significantly reduce polyps in patients with a history of large colon polyps but who did not have FAP. There are also studies that show a reduction in polyps in patients with FAP.
The first participants began the trial in December 2013 and will take the study medication for up to 2 years. Trial results will be submitted to the FDA. If approved, this would be the only approved medication for FAP on the market. To speak to someone and find out if you might be a candidate, and for more information, click here.
Click here to read more about how the HCCF and Cancer Prevention Pharmaceuticals are working together to reduce polyp growth in people with FAP. Once results are published, we will be sure to update this page and notify all of our members.
Watch the replay of the March 25th "live chat," presented by Travis Bray, Hereditary Colon Cancer Foundation and Carol Burke, MD, Cleveland Clinic.
Jeff Jacobs, CEO of Cancer Prevention Pharmaceuticals,
invites you to learn about the Phase III Trial.